EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie

A prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma

Pei Nie, Ben Li, Lei Luo, Feng Hou, Ning Zhang, Hongmin Yang, Xinqi Huang, Ziyuan Zhu, Shuang Ma, Tairui Wu, Jiangtian Xie, Mingxin Zhang und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-07 · 53 (8) · 5002-5012

DOI: 10.1007/s00259-026-07841-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 20.03.2026. Verfasst von Pei Nie und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Qingdao, Shandong, 266003, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Taishan Scholar Foundation of Shandong Province, Natural Science Foundation of Qingdao City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to compare the diagnostic efficacy of 18F-NYM005 PET/CT and 18F-FDG PET/CT in patients with renal cell carcinoma (RCC). METHODS: Patients with renal tumors were prospectively enrolled in the study (ClinicalTrials.gov: NCT06916624). They were divided into three groups: Group I, patients with a primary renal tumor who were scheduled for surgery; Group II, patients with CAIX expression proven by histopathology after surgery who were suspicious of metastatic RCC; and Group Tyrosine Kinase Inhibitors (TKI), RCC patients who received TKI treatment. Paired 18F-NYM005 and 18F-FDG PET/CT scans were performed. Per-lesion diagnostic efficacy and uptake activity of the two tracers in primary tumors, lymph nodes, and distant metastases were compared. RESULTS: Thirty-eight patients (median age, 61.5 y; 32 males) were enrolled, including 12 patients in Group I, 19 patients in Group II, and 7 patients in Group TKI. For detecting primary and metastatic lesions in Group I and Group II, 18F-NYM005 PET/CT demonstrated a higher accuracy (93.86% vs.70.50%, P < 0.001) and a higher specificity (96.95% vs.61.58%, P < 0.001) than 18F-FDG PET/CT, and no significant difference in sensitivity was observed between the two scans (88.80% vs. 85.06%, P = 0.306). In quantitative analysis, no significant difference in SUVmax was found between the18F-NYM005 PET/CT and 18F-FDG PET/CT for primary tumors (14.56 ± 10.31 vs. 9.96 ± 5.56, P = 0.233) and metastatic lymph nodes (5.99 [4.12, 31.71] vs. 4.06 [3.18, 13.01], P = 0.754), and the SUVmax of the distant metastases was higher (7.92 [2.92, 13.40] vs. 2.49 [1.12, 5.37], P < 0.001) in 18F-NYM005 PET/CT than that in 18F-FDG PET/CT. In Group TKI, the SUVmax of the primary and metastatic lesions was lower (1.59 [1.16, 3.25] vs. 6.76 [5.11, 13.01], P < 0.001) in 18F-NYM005 PET/CT than that in 18F-FDG PET/CT. CONCLUSION: 18F-NYM005 PET/CT offers a high diagnostic efficacy for detecting primary tumors and distant metastases in patients with RCC, while it might be of limited value in identifying metastatic lymph nodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Carcinoma, Renal CellKidney NeoplasmsHumansMaleMiddle AgedFemaleProspective StudiesAgedRadiopharmaceuticals

Stichwörter der Autor:innen

18F-FDG18F-NYM005Carbonic anhydrase IXPET/CTRenal cell carcinoma

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Qingdao, Shandong, 266003, China.
  • PET Center, The Affiliated Hospital of Qingdao University, No. 59, Haier Road, Qingdao, Shandong, 266061, China.
  • Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Qingdao, Shandong, 266003, China.
  • Department of Pathology, The Affiliated Hospital of Qingdao University, No. 59, Haier Road, Qingdao, Shandong, 266061, China.
  • Department of Urology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Qingdao, Shandong, 266003, China. dr.zmx@qdu.edu.cn.
  • PET Center, The Affiliated Hospital of Qingdao University, No. 59, Haier Road, Qingdao, Shandong, 266061, China. ygj_2815@qdu.edu.cn.

ORCID-Profile: Zhenguang Wang

Förderung

  • Taishan Scholar Foundation of Shandong Province
  • Natural Science Foundation of Qingdao City

Zitieren

APA

Nie, P., Li, B., Luo, L., Hou, F., Zhang, N., Yang, H., Huang, X., Zhu, Z., Ma, S., Wu, T., Xie, J., Zhang, M., Yang, G., & Wang, Z. (2026). A prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 53(8), 5002-5012. https://doi.org/10.1007/s00259-026-07841-2

Vancouver

Nie P, Li B, Luo L, Hou F, Zhang N, Yang H, et al. A prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(8):5002-5012. doi:10.1007/s00259-026-07841-2

BibTeX
@article{Nie2026,
  author = {Nie, Pei and Li, Ben and Luo, Lei and Hou, Feng and Zhang, Ning and Yang, Hongmin and Huang, Xinqi and Zhu, Ziyuan and Ma, Shuang and Wu, Tairui and Xie, Jiangtian and Zhang, Mingxin and Yang, Guangjie and Wang, Zhenguang},
  title = {A prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {8},
  pages = {5002--5012},
  doi = {10.1007/s00259-026-07841-2}
}
Kostenlos starten →